ArticleMolecular imaging and biology2022
Evaluation of
Article in Molecular imaging and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01739348 (A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Critical review of partial volume correction methods in PET and SPECT imaging: benefits, pitfalls, challenges, and future outlook.European journal of nuclear medicine and molecular imaging · 2026Review
- Follicle-stimulating hormone linked to cognitive decline and amyloid burden in postmenopausal women.Frontiers in aging neuroscience · 2025Article
- It's good to know what to BACE the specificity of your inhibitors on.The Journal of clinical investigation · 2024Article
- Development of a prediction model for cognitive impairment of sarcopenia using multimodal neuroimaging in non-demented older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic.Translational psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe BACE inhibitor verubecestat was previously found to reduce amyloid load as assessed by PROCEDURES: The analyses addressed (1) identification of an optimal
resultsThe optimal subcortical white matter and pons SUVr cutoffs were determined to be 0.69 and 0.62, respectively. The effect size to detect longitudinal change was higher for subcortical white matter (1.20) than pons (0.45). Hence, subcortical white matter was used as the reference region for the EPOCH PET substudy. In EPOCH, uncorrected baseline SUVr values correlated strongly with MZ PVC (r
conclusionsTreatment-related CLINICAL
trial registrationclinicaltrials.gov NCT01739348.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.